Please provide your email address to receive an email when new articles are posted on . In a comparison of two erectile dysfunction medications in men with stable CAD, phosphodiesterase type 5, or ...
Use of a phosphodiesterase type-5 (PDE5) inhibitor was associated with a lower risk for death and cardiovascular events than alprostadil for the treatment of erectile dysfunction in men with stable ...
Men with coronary artery disease who used phosphodiesterase-5 (PDE-5) inhibitors for erectile dysfunction had fewer adverse cardiovascular events than those taking the prostaglandin drug alprostadil ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results